Biotech Values

[DewDiligence]

The HIV market continues to grow nicely in the US and
EU thanks to increased testing, which has been facilitated
by recent legislation (#msg-31419107).

Here are some data** on penetration and market share
as provided by GILD on its 3Q08 CC:


US patients (all lines)
154K on Atripla (28% share)
192K on Truvada (35% share)
23K on Viread (4% share)
===
369K on tenofovir in some form (67% share)
182K on non-tenofovir regimens (33% share)
===
551K total patients, +8% year-over-year


US patients (first-line only)
Atripla: 55% share
Truvada: 30% share
Viread: negligible share
===
Tenofovir in some form: 85% share


Patients in top-5 EU countries (all lines)
*9K on Atripla (3% share)
112K on Truvada (42% share)
59K on Viread (23% share)
===
180K on tenofovir in some form (68% share)
85K on non-tenofovir regimens (32% share)
===
265K total patients, +7% YoY


Top-5 EU countries (first-line only)
Tenofovir in some form: 55% share


*Not yet reimbursed in France.
**As of the end of 2Q08.


<font size=3><font color=red> “The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”